Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acorda Therapeutics Inc.

www.acorda.com

Latest From Acorda Therapeutics Inc.

Sunovion Plans September Launch For Parkinson’s 'Off' Episode Drug Kynmobi

Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.

Approvals Neurology

Biogen’s Fampyra Is Felled In Canada

More than a dozen claims in a Canadian patent shielding Biogen’s Fampyra treatment for multiple sclerosis have been cut following challenges launched by two generics firms.

Intellectual Property Legal Issues

Alkermes’ Pops Lays Out Novel Drug Vision For Year Ahead

CEO Richard Pops said the company will leverage in-house expertise for internally and externally developed neuroscience assets, but partner selectively to advance its IL-2 protein in cancer. 

Business Strategies Neurology

J.P. Morgan Stockwatch: No Substitute For M&A

Stock market reaction to the first day’s news from the 38th J.P. Morgan Healthcare conference in San Francisco was negative, probably because expectations for a continuation of December’s bumper M&A bonanza were too high.

M & A Advisory Committees
See All

Company Information

UsernamePublicRestriction

Register